

HOUSE BILL 578

J1

2lr2180
CF SB 323

By: **Delegates Kaiser, Carr, Charkoudian, Landis, Lehman, Moon, Palakovich Carr, Patterson, Pena-Melnyk, and P. Young**

Introduced and read first time: January 31, 2022

Assigned to: Health and Government Operations

A BILL ENTITLED

1 AN ACT concerning

2 **Maryland Medical Assistance Programs – Prior Authorization for Drug**
3 **Products to Treat an Opioid Use Disorder – Prohibition**

4 FOR the purpose of prohibiting the Maryland Medical Assistance Program and the
5 Maryland Children’s Health Program from applying a prior authorization
6 requirement for certain drug products when used to treat an opioid use disorder; and
7 generally relating to Maryland medical assistance programs and the coverage of
8 drug products.

9 BY adding to

10 Article – Health – General
11 Section 15–150
12 Annotated Code of Maryland
13 (2019 Replacement Volume and 2021 Supplement)

14 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
15 That the Laws of Maryland read as follows:

16 **Article – Health – General**

17 **15–150.**

18 **THE PROGRAM AND THE MARYLAND CHILDREN’S HEALTH PROGRAM MAY**
19 **NOT APPLY A PRIOR AUTHORIZATION REQUIREMENT FOR A PRESCRIPTION DRUG:**

20 **(1) WHEN USED FOR TREATMENT OF AN OPIOID USE DISORDER; AND**

21 **(2) THAT CONTAINS METHADONE, BUPRENORPHINE, OR**
22 **NALTREXONE.**

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
2 October 1, 2022.